|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,370.20 INR | -0.79% |
|
-2.48% | -38.02% |
| 08/12 | Concord Biotech says CFO Lalit Sethi to retire | RE |
| 08/12 | Concord Biotech's CFO Resigns; Shares Down 3% | MT |
Business description: Concord Biotech Limited
Number of employees: 1,571
Sales by Activity: Concord Biotech Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Manufacturing and trading in pharmaceutical products | 616.4Cr | 712.93Cr | 853.17Cr | 1.02TCr | 1.2TCr |
Geographical breakdown of sales: Concord Biotech Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
India | 252.65Cr | 337.41Cr | 432.13Cr | 534.21Cr | 661.83Cr |
Others | 204.5Cr | 244.07Cr | 273.78Cr | 374.75Cr | 400.28Cr |
America | 159.25Cr | 131.45Cr | 147.25Cr | 107.98Cr | 137.97Cr |
Executive Committee: Concord Biotech Limited
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 73 | 10/05/2000 | |
| Chief Executive Officer | - | 01/09/2011 | |
Lalit Sethi
DFI | Director of Finance/CFO | 59 | 14/03/2022 |
Subhash Nair
PRN | Corporate Officer/Principal | - | 10/04/2017 |
Manoj Kumar
PRN | Corporate Officer/Principal | - | - |
Composition of the Board of Directors: Concord Biotech Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 30/06/2008 | |
| Chairman | 73 | 10/05/2000 | |
| Director/Board Member | 81 | 31/01/2017 | |
Jayaram Easwaran
BRD | Director/Board Member | 73 | 14/06/2022 |
Bharti Khanna
BRD | Director/Board Member | 57 | 31/01/2017 |
| Director/Board Member | 65 | 24/05/2022 | |
| Director/Board Member | 79 | 14/06/2022 | |
| Director/Board Member | - | 01/09/2011 |
Company details: Concord Biotech Limited
Concord Biotech Ltd.
B-Wing, Mondeal Heights
380015, Ahmedabad
+91 79 6813 8700
http://www.concordbiotech.com
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.79% | -2.48% | -34.54% | - | 160.75Cr | |
| +2.84% | +3.20% | -4.07% | -0.43% | 7.45TCr | |
| +1.19% | -2.54% | -35.30% | -39.34% | 5.82TCr | |
| -0.62% | +0.38% | +33.43% | +235.89% | 5.36TCr | |
| +0.24% | +66.90% | +66.90% | +66.90% | 5.24TCr | |
| -2.84% | -4.56% | +10.35% | -39.55% | 2.6TCr | |
| +0.98% | -5.32% | +32.59% | +16.71% | 1.87TCr | |
| +0.18% | -8.88% | +119.27% | +159.38% | 1.84TCr | |
| -0.66% | -13.12% | +42.61% | +1,004.75% | 1.66TCr | |
| -0.04% | -.--% | +58.67% | +154.72% | 1.4TCr | |
| Average | +0.05% | -1.67% | +28.99% | +173.23% | 3.34TCr | |
| Weighted average by Cap. | +0.58% | -0.58% | +22.41% | +104.95% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CONCORDBIO Stock
- Company Concord Biotech Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition